Startups
LabGenius
https://labgeni.usBiopharmaceutical company developing protein therapeutics with a machine learning-driven evolution engine.
Summary
Insights
LabGenius has significant potential due to its innovative approach combining biopharmaceutical development with advanced machine learning. Located in London and targeting a B2B market, the company uses cutting-edge technology to accelerate the development of protein therapeutics. Traditional protein engineering methods are slow and expensive, leading to higher costs and less effective drugs. By using a machine learning-driven evolution engine, LabGenius can expedite therapeutic development, offering a faster and more cost-effective solution. With backing from Kindred Capital and Atomico, LabGenius is poised to disrupt conventional drug development and establish itself as a market leader.
Total Funding
$83.2M
- Seed (2017) $3.7M
- Series B (2024) $44.5M
- Series A (2019) $10.0M
- Unknown (2020-01-01) $25.0M
Investors
Kindred Capital Seed
System.One Seed
Acequia Capital Seed
Atomico Series B
Octopus Ventures Series B
Octopus Ventures Series B
Lux Capital Series B
M Ventures Series B
Felicis Ventures Series A
Obvious Ventures Series A
Full Company Profile
- Access details of the company management, and other intelligence on this company by registering for Seedtable